Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2009

ROLE OF BCL-2 FAMILY MEMBERS TO PROMOTE
GLUCOCORTICOID –INDUCED APOPTOSIS BY MEK INHIBITORS
IN LEUKEMIC CELLS
ANILA RAMBAL
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Environmental Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/1790

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

Center for Environmental Studies

Virginia Commonwealth University

This is to certify that the thesis prepared by Rambal Anila Ashok entitled ROLE OF
BCL-2 FAMILY MEMBERS TO PROMOTE GLUCOCORTICOID –INDUCED
APOPTOSIS BY MEK INHIBITORS IN LEUKEMIC CELLS has been approved by her
committee as satisfactory completion of the thesis requirement for the degree of Master
of Science in Environmental Studies

Dr. Hisashi Harada, Department of Internal Medicine

Dr. Peter L. DeFUR, Center for Environmental Studies

Dr. Rima B. Franklin, Department of Biology

Dr. Greg Garman, Director of Center for Environmental Studies

Dr. Thomas Huff, Vice-Provost for Life Sciences

Dr. F. Douglas Boudinot, Dean of the Graduate School

20th April, 2009

© Rambal Anila Ashok, 2009
All Rights Reserved

ROLE OF BCL-2 FAMILY MEMBERS TO PROMOTE GLUCOCORTICOID –
INDUCED APOPTOSIS BY MEK INHIBITORS IN LEUKEMIC CELLS
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science, Environmental Studies at Virginia Commonwealth University.
By

RAMBAL ANILA ASHOK
Master of Philosophy in Environmental Science and Engineering
Pondicherry University, India, 2006

Director: DR. HISASHI HARADA
ASSISTANT PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE

Virginia Commonwealth University
Richmond, Virginia
May 2009

Acknowledgement
I would like to acknowledge the support and help of all the people who made it possible
for me to achieve my goals and complete my thesis in the desired manner.
I am grateful to my advisor, Dr. Hisashi Harada, who offered me a position of Research
Assistant in his laboratory. He also inculcated scientific discipline and curiosity in me.
He helped me progress academically and gain valuable insight in the subject. I also thank
Dr. Steve Grant and his laboratory members, for providing some of the needed materials.
I also thank all of them for allowing me to be a part of their research discussion groups,
these group meetings enabled me to understand the subject in-depth and provided me
with lot of ideas and valuable suggestions to carry on my project. I also thank Zarah
Panaguiton for being a very supportive and helpful colleague.
I would like to express my appreciation to Dr. Peter Defur and Dr. Cliff Fox for enabling
me to pursue my thesis and providing me with relentless support. Being an international
student, their help and guidance was very beneficial. It helped me complete my degree
and thesis work in the required manner.
I would like to express my heartfelt gratitude to Dr. Rima Franklin, for being a constant
source of support and motivation. Also, thanks to Leukemia Research foundation for
supporting my research.
And finally, my appreciation goes to my family and friends without whom it would not
have been possible for me to be here.

iv

Table of Contents
Page
Acknowledgement ...............................................................................................................v
List of Figures ................................................................................................................... vi
Abstract

.................................................................................................................. vii

Introduction

.....................................................................................................................1

Hypothesis

....................................................................................................................20

Materials and Methods.......................................................................................................21
Results

...................................................................................................................24

Discussion

....................................................................................................................35

Literature cited ...................................................................................................................39
Vita

....................................................................................................................45

v

List of Figures
Page
Figure 1: Difference between necrosis and apoptosis..........................................................3
Figure 2: Intrinsic Pathway to carry out apoptosis. .............................................................6
Figure 3: The three classes of BCL-2 family member proteins. ........................................9
Figure 4: Chemotherapy triggers the intrinsic pathway.....................................................11
Figure 5: Classical and alternative pathway for GC-induced cell death............................14
Figure 6: RAS/REF/MEK/ERK pathway. .........................................................................19
Figure 7: CCRF-CEM (T-ALL) cells show an increase in apoptosis when co-treated with
Dexamethasone and PD184352. .........................................................................25
Figure 8: Western blot analysis of the BCL-2 family member proteins............................27
Figure 9a: Down-regulation of BIM by shRNA ................................................................29
Figure 9b: BIM is required for cell death induced by Dexamethasone and PD184352...29
Figure 10a: Down-regulation of BAD by shRNA. ............................................................31
Figure 10b: BAD is dispensable for cell death induced by Dexamethasone and
PD184352.
............................................................................................................................................31
Figure 11a: The expression of PUMA in CEM/shPUMA clone 37 and clone 47. ..........33
Figure 11b: Cell death in CEM/shPUMA clone 37 and clone 47 treated with Dex and/or
PD184352. ......................................................................................................................33

vi

Abstract

ROLE OF BCL-2 FAMILY MEMBERS TO PROMOTE GLUCOCORTICOID –
INDUCED APOPTOSIS BY MEK INHIBITORS IN LEUKEMIC CELLS

By Rambal Anila Ashok, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science, Environmental Studies at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr. Hisashi Harada
Assistant Professor, Department of Internal Medicine

Glucocorticoids (GC) are common components of many chemotherapeutic regimens for
lymphoid malignancies.

GC-induced apoptosis involves an intrinsic BCL-2 family-

regulated pathway. It has been shown that BIM (BCL-2 interacting mediator of cell
death), a BH3-only pro-apoptotic protein, is up-regulated by dexamethasone (Dex)
treatment in acute lymphoblastic leukemia (ALL) cells. Furthermore, BIM is inactivated
by extracellular signal-regulated kinase (ERK)-mediated phosphorylation. We therefore
vii

hypothesized co-treatment with Dex and MEK/ERK inhibitors would promote apoptosis
in ALL cells through BIM up-regulation and activation. We show here that a MEK
inhibitor, PD184352 synergistically enhances Dex lethality in CCRF-CEM (T-ALL)
cells. Co-treatment with Dex and PD184352 results in BIM accumulation. Downregulation of BIM by short-hairpin RNA in CCRF-CEM cells suppressed apoptosis by
Dex/PD184352 co-treatment.

In contrast, another BH3-only protein, BAD is

dispensable. Thus, BIM is a critical molecule in this regimen, and targeting BIM by
drugs combination could be effective on ALL and possibly other malignancies.

Key words: Leukemia, BCL-2, apoptosis, glucocorticoids, MEK inhibitor
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Introduction

Cancer and Apoptosis:
Cancer can be defined as a condition in which mutated cells divide without
control and are able to spread to adjacent or other tissues. Cancers are of various types
depending upon the cells from where they originate.
Carcinoma occurs in cells covering the body surfaces such as breast, colon and is the
most frequent type of cancer.
Sarcoma occurs in cells of supporting tissues such as cartilage, fat, muscle and bone.
Lymphoma occurs in the lymph nodes and impairs the body’s immune system.
Leukemia occurs in the blood cells of the bone marrow and they circulate and
accumulate in the bloodstream.1
Cancer cells can spread to other parts of the body through the blood and
lymphatic systems via two mechanisms: invasion and metastasis. Invasion refers to the
direct migration and penetration by cancer cells into neighboring tissues. Metastasis
refers to the ability of cancer cells to penetrate into lymphatic and blood vessels and then
invade normal tissues elsewhere in the body via the circulation system.

1

Cells have a finite lifespan and cell death occurs mainly as a result of passive
necrotic processes or due to an active process of programmed cell death termed
apoptosis. Necrosis is premature death of cells, caused by external factors like infections
or trauma. Necrosis may prove to be fatal and it is in contrast to apoptosis. Figure 1
illustrates the difference between necrosis and apoptosis.
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Figure 1: Difference between necrosis and apoptosis. Cells undergoing necrosis
initially swell and their internal components or organelles break down.

The cells

eventually rupture and spill debris that leads to local inflammation. This inflammation
can then result in the death of adjacent cells. During apoptosis, the cell breaks up into
several smaller bodies that are still surrounded by a membrane. These "apoptotic bodies"
then are engulfed and destroyed by scavenging cells. Reference (2): Goodlett RC
3

Apoptosis plays an important role both in human embryonic development and in
adult tissue homeostasis. Apoptosis is the most common mechanism by which the body
eliminates damaged or unneeded cells without local inflammation from leakage of cell
contents. In normal cells, apoptosis is initiated in response to developmental cues, cell
stress, and changes in growth factor signaling.

Dysregulation of apoptosis is implicated

in a variety of diseases states. Accelerated cell death is implicated in the pathogenesis of
a number of diseases, including Alzheimer's disease and acquired immunodeficiency
syndrome (AIDS). Conversely, an inappropriately low rate of apoptosis can give rise to
cancer or autoimmune disorders.
The balance of cell proliferation and apoptosis genetically controls cell growth;
dysregulation of this balance causes tumor development. One group of genes implicated
in the development of cancer is "oncogenes." Oncogenes are activated by overexpression
and/or mutations, resulting in uncontrolled cell growth.

A second group of genes

implicated in cancer are the "tumor suppressor genes." Tumor suppressor genes are the
genes whose absence can lead to cancer. One example of the tumor suppressor genes
called "p53" can normally trigger apoptosis. In cells that have undergone irreversible
DNA damage, p53 protein eventually initiates cell suicide, thereby preventing the
genetically damaged cell from growing out of control. Thus, activation of oncogenes and
inactivation of tumor suppressor genes are the key hallmarks of cancer and are critical for
cancer development and tumor cell survival.3-5

4

Apoptosis is executed through two major signaling pathways — the 'intrinsic' and
the 'extrinsic' pathways .Figure 2. shows the diagrammatic representation of the intrinsic
pathway The intrinsic pathway is triggered within the cell by developmental cues or
severe cell stress, such as DNA damage. The extrinsic pathway is activated when a proapoptotic ligand, for example, Apo2L/TRAIL (apoptosis-inducing ligand 2/tumor
necrosis factor-related apoptosis-inducing ligand) binds to pro-apoptotic receptors, DR4
and DR5. The extrinsic and intrinsic pathways converge via activation of intracellular
enzymes called 'caspases'. The caspase cascade ultimately triggers cell death through the
destruction of cellular proteins, which are important for cell viability.

5

Figure 2: Intrinsic Pathway to carry out apoptosis. External stimuli such as UV or
chemotherapeutic treatments trigger apoptosis through the BCL-2 family proteins
localized at mitochondria. The release of cytochrome c from mitochondria and
subsequent caspase 9 activation leads to cell death. Reference (6): Andersen MH
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BCL-2 Family Member Proteins:
The intrinsic pathway relies on the balance between pro- and anti-apoptotic
members of the B-cell lymphoma-2 (BCL-2)-family proteins. They play an important
role in the regulation of apoptosis as they have the ability to regulate mitochondrial
cytochrome c release. The BCL-2 family is subdivided into three main groups based on
regions of one to four BCL-2 homology (BH1-BH4) domains and function. Multidomain anti-apoptotic subfamily which contains trans-membrane domains (TM) is
typically associated with membranes (e.g., BCL-2, MCL-1, BCL-XL). Multi-domain
pro-apoptotic BAX-like subfamily (e.g. BAX, BAK) lacks BH4 domains and promotes
apoptosis by forming pores in mitochondrial outer membranes. BAX was the first deathinducing protein identified as part of the BCL-2 family. BH3-only pro-apoptotic proteins
is a structurally diverse group of proteins that only display homology within the small
BH3 motif (e.g., BAD, BID, BIM, PUMA). The anti-apoptotic BCL-2 proteins inhibit
apoptosis by preventing BH3-only protein-induced oligomerization of BAX and/or BAK
at mitochondrial outer membranes, which would otherwise lead to the release of
cytochrome c. The anti-apoptotic BCL-2 proteins differentially bind to the BH3-only
proteins. BH3-only proteins like BID and BIM interact with all anti-apoptotic BCL-2
proteins, whereas others like NOXA interact only with certain BCL-2-family members.
To date, over twenty different BCL-2 family members have been identified.7-12
BCL-2 family member proteins are essential for normal tissue development and
homeostasis. Figure 3 illustrates the BCL-2 family member proteins along with their
7

molecular weights, BH1-4 regions, and trans-membrane domains. Homo- and heterodimerization among the BCL-2 family proteins is one mechanism that regulates the
apoptotic activity of these proteins. BH3-only proteins, when over expressed, promote
apoptosis and are responsible for activating or suppressing pro- and anti-apoptotic BCL-2
proteins.

It is now clear that activation of BH3-only proteins by apoptotic stimuli

initiates mitochondria-dependent cell death pathway. The intrinsic pathway begins with
cell stress to activate BH3-only proteins, which cause cytochrome c release from
mitochondria by activating BAX and/or BAK. The anti-apoptotic BCL-2 family of
proteins prevents this process. Cytochrome c released from mitochondria binds the
adaptor apoptotic protease activating factor-1 (APAF-1), forming a large multi-protein
structure known as the apoptosome. The apoptosome then recruits and activates caspase9, which in turn activates the downstream effector caspases, including caspase-3, -6, and
-7, leading to target protein degradation.

8

Figure 3: Three classes of BCL-2 family member proteins. They include antiapoptotic, pro-apoptotic and BH3-only proteins. The figure also shows the transmembrane domain along with the BH1-4 regions. Reference (13): Taylor, CR
9

Chemotherapy:
Chemotherapy is the general term for treatments with chemical agents to stop
cancer cells from growing.

Chemotherapy can eliminate cancer cells at sites great

distances from the original cancer. As a result, chemotherapy is considered a systemic
treatment and causes therapeutic activation of apoptosis in cancer cells. Commonly used
anticancer drugs can induce tumor cell death by apoptosis. Altered expression of the
BCL-2

family

proteins,

either

overexpression

of

pro-survival

proteins

or

decreased/altered expression of pro-apoptotic members has been identified in many
cancer cell types and may contribute to the resistance of these tumor cells to
chemotherapeutic agents. This observation, together with the central role of the BCL-2
family proteins in cell death pathways, makes these proteins attractive targets to kill
tumor cells or to sensitize them to death induced by common cytotoxic drugs. Figure 4
illustrates the intrinsic pathway, which gets triggered when DNA damage occurs due to
chemotherapeutic drugs Thus, targeting the intrinsic pathway by chemotherapeutic drugs
is a strategy to kill tumor cells. In the present study we examine the role of two
chemotherapeutic drugs - glucocorticoids and MEK inhibitors.

10

Figure 4: Chemotherapy triggers the intrinsic pathway.
Chemotherapy triggers DNA damage which activates the BCL-2 family member proteins
leading to cytochrome c release. Cytochrome c leads to formation of apoptosome, which
activates caspases and eventually causes cell death.
Reference: http://www.researchapoptosis.com/apoptosis/pathways/intrinsic/index.m
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Glucocorticoids and their interaction with the BCL-2 family member proteins:
Glucocorticoids (GCs): These are a class of steroid hormones produced in the adrenal
glands. GC induces apoptosis in certain lymphoid cells and plays an important role in the
treatment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid
malignancies. Figure 5 explains that GC induces cell death via two possible pathways:

The classic pathway: GC might induce cell death by directly regulating genes
controlling cell survival and apoptosis, or via (de)regulating genes or gene networks
leading to cellular distress, which in turn constitutes an apoptotic stimulus. In both
scenarios, members of pro- and anti-apoptotic BCL-2 family proteins, referred to as the
‘BCL-2 rheostat’, might be involved either as direct GR targets or as sensors for
potentially harmful GC effects. GC-induced intrinsic pathway regulated by the BCL-2
family proteins can be broadly classified into three stages:



Initiation stage: GC binds to the glucocorticoid receptor (GR), a ligand-activated
transcription factor of the nuclear receptor superfamily that resides in the
cytoplasm. Then GR translocates into the nucleus and modulates gene expression
via binding to specific DNA response elements or by protein-protein interactions
with other transcription factors.

12



Decision stage: Pro- and anti-apoptotic BCL-2 family proteins regulate the
execution of apoptosis at the mitochondrial level. This leads to the release of
cytochrome c from the intermembrane space of mitochondria into cytosol.



Execution stage: The release of cytochrome c triggers the activation of caspases,
which cleaves a variety of substrates and also results in the activation of
endonucleases leading to DNA cleavage. These events finally lead to cell death

The alternative pathway: Apart from regulating the BCL-2 family members, GC has
dramatic effects on metabolism in numerous lymphocytic and non-lymphocytic cells.
Thus, anabolic processes (such as glucose uptake, amino acid transport, ATP production,
RNA polymerase activity, nucleoside accumulation, protein and nucleic acid
biosynthesis) are decreased and catabolic processes (such as protein and RNA
degradation) stimulated. In most tissues, GR is subject to negative feedback, making the
above (and/or perhaps other) potentially harmful GC-mediated events transient. In cells
undergoing GC-induced apoptosis, GR is not repressed - to the contrary, there are several
examples where sensitivity is associated with GR auto-induction. In the continuous
presence of GR (and even more so in the case of GR auto-induction), the above GC
effects will become permanent and, given sufficient time, lead to a state incompatible
with cellular survival.14-20
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Figure 5: Classical and alternative pathway for GC-induced cell death. Left side of
the figure explains rapid apoptosis induced by GC by directly regulating typical apoptosis
genes, possibly those controlling the “BCL-2 rheostat”. In the presence of (oncogenic)
overexpression of anti-apoptotic BCL-2 family members (represented by BCL-2 in the
figure), this mechanism may be delayed allowing a second mechanism to take place
(right side of the figure) that proposedly critically depends on GR auto-induction
("positive feed-back loop"). In its presence, otherwise transient, detrimental GC effects
(catabolic effects with reduced macromolecule biosynthesis and others) may become
permanent and thus incompatible with cellular survival. Reference (21): Renner K
14

Dexamethasone (Dex) is a member of the synthetic glucocorticoid and is used in
chemotherapy to treat leukemia/lymphoma.

The current understanding of the

mechanisms of Dex-induced apoptosis is as follows:
 Dex-induced apoptosis is regulated by the BCL-2 family proteins, which play
vital roles in the decision stage.
 It has been shown that BIM (BCL-2 Interacting Mediator of cell death), a BH3only pro-apoptotic BCL-2 family protein, is induced by Dex in leukemic cells and
plays a critical role in Dex-induced apoptosis.22
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RAS-RAF-MEK-ERK pathway:
The RAS/RAF/MEK (mitogen-activated protein kinase/ERK kinase)/ERK
(extracellular signal-regulated kinase) pathway has diverse effects which can regulate cell
cycle progression, survival or differentiation.

Abnormal activation of this pathway

occurs in human cancer due to the activation of the upstream molecules by (1) mutations
at membrane receptors such as FLT-3, KIT, or FMS, (2) overexpression of wild-type or
mutated EGFR, or (3) chromosomal translocations such as BCR-ABL. Furthermore, this
cascade also regulates the activity of many proteins involved in apoptosis by the posttranslational phosphorylation of apoptotic regulatory molecules including BAD, BIM,
MCL-1, caspase-9 and more controversially BCL-2.
RAS is an upstream activator of the RAF/MEK/ERK kinase cascade; it is a small
GTP-binding protein. Four RAS proteins have been identified, namely Ha-RAS, N-RAS,
Ki-RAS 4A and Ki-RAS 4B. The two isoforms of Ki-RAS are produced from the same
gene by alternative splicing.

RAS proteins show varying abilities to activate the

RAF/MEK/ERK and PI3K/AKT cascades.
The mammalian RAF gene family consists of A-RAF, B-RAF and RAF-1 (CRAF). RAF is a serine/threonine (S/T) kinase and is normally activated by a complex
series of events including: (i) recruitment to the plasma membrane mediated by an
interaction with RAS; (ii) dimerization of RAF proteins; (iii) phosphorylation
/dephosphorylation on different domains; (iv) disassociation from the RAF kinase
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inhibitory protein (RKIP) and (v) association with scaffolding complexes [e.g. kinase
suppressor of RAS (KSR)]. RAF activity is further modulated by chaperonin proteins.
MEK is a tyrosine (Y)- and S/T-dual specificity protein kinase. Its activity is
positively regulated by phosphorylation on S residues in the catalytic domain mediated
by RAF. All three RAF family members are able to phosphorylate and activate MEK but
different biochemical potencies have been observed (B-RAF > RAF-1 > A-RAF). The
predominant downstream target of MEK is ERK. In contrast, downstream ERK has
multiple targets. Thus, therapeutic targeting of MEK is relatively specific.23-27
ERK are S/T kinases and their activities are positively regulated by
phosphosphorylation mediated by MEK.

ERK can directly phosphorylate many

transcription factors including ETS-1, c-JUN and c-MYC. ERK can also phosphorylate
and activate the 90 kDa ribosomal S6 kinase (p90RSK), which then leads to the
activation of the transcription factor CREB. ERK has over 160 downstream targets and
activates more then 70 substrates. Figure 6 explains the RAS/REF/MEK/ERK pathway.
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MEK inhibitors:
The RAF/MEK/ERK pathway is an important pathway to target for therapeutic
intervention. Inhibitors of RAS, RAF, and MEK and some downstream targets have been
developed and many are currently in clinical trials.
Blocking ERK activity via small-molecule MEK inhibitors has come to the
forefront as an exciting approach in cancer therapeutics. PD98059 was the first specific
MEK inhibitor described.

It was identified by screening a compound library for

inhibitors with an assay that measured phosphorylation of an ERK target protein in the
presence of both MEK and ERK. A second MEK inhibitor, U0126 was also identified by
screening a compound library using an assay designed to find an inhibitor that could
antagonize activator protein-1-driven transcription without blocking the transcription of
glucocorticoid response elements. PD184352 (CI-1040), the MEK inhibitor used in our
current study, was the first small-molecule MEK inhibitor that proceeded to clinical
testing. PD184352 was developed based on compounds and structures identified during
the screening that led to the identification of PD98059, but had improved potency and
selectivity. 28-31
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Figure 6: RAS/RAF/MEK/ERK pathway.

RAF proteins have been identified as

critical signaling intermediates between RAS and ERKs. MEK inhibitors block the
pathway, which prevents the activation of transcription factors regulating gene expression
for cell proliferation, survival, and differentiation. Reference (32): Pritchard C.
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Hypothesis

We hypothesize that co-treatment of Dex and MEK inhibitors will synergize cell
death in leukemic cells by the mechanism that a) GCs can up-regulate BIM; and b)
pharmacologic MEK inhibitors may further potentiate BIM activation by blocking BIM
phosphorylation and degradation.33 We specifically aim to understand the role of the
following BH3-only proteins in the intrinsic pathway.
 BIM: as it is induced by Dex and is activated by MEK inhibitors.
 BAD: as it acts downstream of the MEK/ERK pathway.
 PUMA: as it plays a role in Dex-induced cell death in non-leukemic lymphoid
cells.

20

Materials and Methods

Cell line and culture:
The human T-ALL cell line CCRF-CEM was purchased from the American Tissue
Culture Collection.

The cells were cultured in RPMI 1640 medium (Invitrogen)

supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen), and
streptomycin/penicillin G (Invitrogen) at 37 oC in a 5% CO2 incubator.

Chemicals and antibodies:
Dexamethasone and Propidium Iodide (PI) were purchased from Sigma. Antibodies for
Western blot were purchased as follows: BIM from Calbiochem; BAX (N-20), -tubulin, phospho-ERK, and ERK from Santa Cruz Biotechnology; BAK from
Upstate/Millipore; BCL-2 from Sigma; MCL-1 from Assay Designs; BAD, PUMA, and
BCL-XL from Cell Signaling Technology; GAPDH from Abcam. A phospho-S65 BIM
antibody was developed in our lab as described previously.33 A MEK inhibitor,
PD184352 was kindly provided by Dr. Steven Grant at Virginia Commonwealth
University. Annexin V-FITC was purchased from BD-Pharmingen.
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Plasmid construction and transfection:
For down-regulation of BIM by short-hairpin RNA (shRNA), pSR-BIM was constructed
by inserting the target sequence for human BIM (GenBank AF032457, nucleotide 37-56;
GACCGAGAAGGTAGACAATT) into pSUPER.retro.puro (Oligoengine) according to
the manufacture’s protocol.

As control, a scrambled, non-specific sequence

(AATTCTCCGAACGTGTCACGT) was inserted into the same vector (pSR-con). For
down-regulation of BAD or PUMA by shRNA, microRNA-adapted shRNA construct
sdesigned against human Bad (5’-ACGTGCTCACTACCAAATGTTA-3’) or human
puma

(5’-ACCATTGCATAGGTTTAGAGAG-3’)

Biosystems.

were

purchased

from

Open

Transfection was performed by electroporation using a Bio-Rad

electroporator. The CEM cells were suspended in RPMI 1640 (4 x 106/400 µl) with 10
µg of DNA and electroporated in 0.4 cm cuvettes at 300 V, 500 µF. Puromycin (2
µg/ml) selection to establish stable clones began 24 hrs after electroporation.

Western Blot analysis:
Cells were pelleted by centrifugation (5000 rpm for 1 min), washed with PBS,
resuspended in lysis buffer {20 mM Tris (pH7.4)/ 137 mM NaCl/ 1 mM DTT/ 1% 3-[(3cholamidopropyl) dimethylammonio]-1-propanesulfonate/ 20 mM NaF/ 10 mM βglycerophosphate, and a protease inhibitor mixture (1:200 dilution; Sigma)}, and kept on
ice for 20 mins. They were then centrifuged at 13,000 rpm for 5 mins in cold room and
the supernatant was used as whole cell lysate. Protein concentration was determined by
22

the Lowry method (Bio-Rad). Equal amounts of proteins were loaded on SDS/PAGE,
transferred to a nitrocellulose membrane, and analyzed by immunoblotting.

Cell Viability assay:
Cells were pelleted by centrifugation, washed with PBS twice, and resuspended in 100 µl
of binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2). Annexin V-FITC (3
µl) and Propidium Iodide (10 µl) were added to the cells and incubated at room
temperature in dark for 15 mins. Four-hundred µl of binding buffer was then added to
the sample followed by flow cytometric analysis with FACScan (Becton Dickinson).

Statistical Analysis:
For flow cytometric analyses of Annexin-V/PI, values represent the means ± SD for three
separate experiments. The significance of differences between experimental variables
was determined using the Student’s t-test.
significant at P < 0.05.
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Values were considered statistically

Results and Conclusions

We first tested our hypothesis that up-regulation of BIM (by Dex) together with
diminished phosphorylation of BIM (by MEK inhibitors) enhances cell death in CCRFCEM (CEM), an acute lymphoblastic leukemia (ALL) cell line. A MEK inhibitor,
PD184352 was used throughout this study. Treatment with PD184352 or Dex alone
shows apoptosis of about 8% and 17% respectively. However, when the cells are cotreated with PD184352 and Dex, apoptosis increases to about 60% (Fig. 7). Treatment of
as low as 30 nM Dex significantly increases cell death in combination with 5 M of
PD184352. The PD184352 dose-response curve reveals that as low as 1 M PD184352
significantly increases the toxicity of 100 nM Dex. Time course analysis indicates that
simultaneous exposure of 100 nM Dex and 5 M PD184352 results in little apoptosis
after 24 hrs, but extensive at later time points (data not shown). We also observe Dex
and PD184352 interactions in several other ALL cell lines. These results indicate that
minimally toxic concentrations of MEK inhibitors markedly potentiate the lethality of
low concentrations of dexamethasone in ALL cells.
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Figure 7: CCRF-CEM (T-ALL) cells show an increase in apoptosis when co-treated
with Dexamethasone and PD184352.
CEM cells were exposed to 5 M PD184352 (PD) and 100 nM dexamethasone (Dex)
alone or in combination for 48 hrs. Cell death was quantified by Annexin-Vfluorochrome conjugates (Annexin-V-FITC) and propidium iodide staining followed by
flow cytometry analysis.
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Protein expression of the BCL-2 family members was determined by Western blots (Fig.
8). In CEM cells, BIMEL (extra-long) is the most abundant BIM isoform derived by
alternative splicing [BIML (long) and BIMS (short) are the other two isoforms]. We
observe the expression of BIMEL in cells co-treated with PD184352 and Dex is much
more than that in cells treated with PD184352 or Dex alone. Expression of BAD,
PUMA, BAK, BAX, BCL-2, BCL-XL and ERK in the cells remains unchanged under all
four treatment conditions. MCL-1 shows reduced expression when cells are treated with
PD184352 and increased expression with Dex treatment. When cells are co-treated with
PD184352 and Dex, MCL-1 shows similar expression as control.

Expression of

phosphorlyated form of ERK (pERK) is totally abrogated by PD184352 regardless of
Dex treatment, indicating that the ERK activity is inhibited by PD184352 independent of
Dex. GAPDH is used as a loading control. Hence the expression of BIM is correlated
with the percentage of cell death observed in Fig. 7. In contrast, the expression of other
members of the BCL-2 family proteins is not much altered under all four treatment
conditions.
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Figure 8: Western blot analysis of the BCL-2
family member proteins.
CEM cells were treated with 100 nM Dex and/or
5 M PD184352 for 24 hrs. Equal amounts of
total cell extracts were subjected to Western
blotting with the indicated antibodies.
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To examine the significance of BIM, we established the CEM cell clones that express
shRNA for Bim to reduce the expression of endogenous BIM. As control, a scrambled,
non-specific shRNA construct was transfected. Short hairpin RNA (shRNA) is used to
silence gene expression via RNA interference.

BIMEL is highly induced in the

transfected control cells when co-treated with PD184352 and Dex (Fig. 9a), which is also
observed in the parental cells (Fig. 8). The induction of BIMEL in shBIM clone 2 cells is
completely inhibited under all four treatment conditions. In shBIM clone 15 cells, the
induction of BIMEL is partially inhibited in the four treatment conditions. Expression of
pERK in control, shBIM clone 2, and clone 15 cells is nil with PD184352 treatment. In
the case of treatment with Dex, the expression of pERK in all three clones is similar to
the untreated control. Thus, the expression of BIMEL in shBIM clone 2 and 15 is
completely and partially down-regulated, respectively, without affecting the expression
of pERK. The cell death assay (Fig. 9b) illustrates that apoptosis in control cells with cotreatment is around 45% and it is around 8% and 20% in shBIM clone 2 and clone 15
cells respectively. Hence cell death induced by Dex/PD184352 treatment corresponds to
the BIM expression; i.e. apoptosis is completely inhibited in shBIM clone 2 cells and is
partially inhibited in shBIM clone 15 cells as compared to the transfected control clone.
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Figure 9a: Down-regulation of BIM by shRNA.
shBIM clones 2 and 15 were established to down-regulate BIM by shRNA. Cells were
treated with 100 nM Dex and/or 5 M PD184352 for 24 hrs. Equal amounts of total cell
extracts were subjected to Western blotting with the indicated antibodies.

Figure 9b: BIM is required for cell death induced by Dexamethasone and
PD184352.
CEM clones in Fig. 7a were exposed to 5 M PD184352 (PD) and 100 nM
dexamethasone (Dex) alone or in combination for 48 hrs. Cell death was quantified by
Annexin-V-FITC/PI staining followed by flow cytometry analysis.
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We next examined the significance of BAD using the CEM clones that express shRNA
for Bad. We observe that expression of BAD in untreated clone 7 and clone 12 cells is
completely abrogated by the introduction of shBAD (Fig. 10a, left panel). However, the
expression of BIMEL is similar among the transfected control and shBAD clone cells.
When cells are treated with PD184352 and/or Dex, the expression of BAD is still totally
inhibited in shBAD clone 7 cells (Fig. 10a, right panel). In contrast, similar expression of
BIMEL is observed in control and shBAD clone 7 cells. Tubulin is used as a loading
control.

These results indicate that down-regulation of BAD does not affect BIM

expression. The cell death assay (Fig. 10b) shows around 50% of apoptosis in all four
clones co-treated with PD184352 and Dex. This assay confirms that BAD is dispensable
in cell death induced by co-treatment with PD184352 and Dex.
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Figure 10a: Down-regulation of BAD by shRNA.
shBAD clone 7 and 12 were established to down-regulate BAD by shRNA. Cells were
treated with 100 nM Dex and/or 5 M PD184352 for 24 hrs. Equal amounts of total cell
extracts were subjected to Western blotting with the indicated antibodies.

Figure 10b: BAD is dispensable for cell death induced by Dexamethasone and
PD184352.CEM clones in Fig. 8a were exposed to 5 M PD184352 (PD) and 100 nM
dexamethasone (Dex) alone or in combination for 48 hrs. Cell death was quantified by
Annexin-V-FITC/PI staining followed by flow cytometry analysis.
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Finally, we examined the significance of PUMA using the CEM clones that express
shRNA for PUMA to down-regulate PUMA. Since the shRNA plasmid construct harbors
puromycin-resistant gene, we selected two puromycine-resistant CEM clones (shPUMA
clone 37 and clone 47). The expression of PUMA in control, shPUMA clone 37, and
clone 47 was determined when cells were treated with PD184352 and Dex alone or in
combination (Fig. 11a). Tubulin is used as a loading control. We observe that the
expression of PUMA under all conditions is constant. The cell death assay (Fig. 11b)
shows similar amounts of apoptosis induced by Dex and/or PD184352 in between
control, clone 37, and clone 47. These results indicate that the shPUMA construct used is
not working as desired. Thus, this experiment needs to be performed using a different
construct.
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Figure 11a: The expression of PUMA in CEM/shPUMA clone 37 and clone 47.
Cells were treated with 100 nM Dex and/or 5 µM PD184352 for 24 hrs. Equal amounts
of total cell extracts were subjected to Western blotting with the indicated antibodies.

Figure 11b: Cell death in CEM/shPUMA clone 37 and clone 47 treated with Dex
and/or PD184352.
CEM clones were exposed to 5 µM PD184352 (PD) and 100 nM dexamethasone (Dex)
alone or in combination for 48 hrs. Cell death was quantified by Annexin-V-FITC/PI
staining followed by flow cytometry analysis.
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Based on the above results, we conclude that:
 Combination of dexamethasone and PD184352 synergistically induces apoptosis
in ALL cells.
 BIM plays a significant role in apoptosis induced by co-treatment with PD184352
and Dex.
 BAD knock-down experiments confirm that BAD is dispensable for cell death in
this treatment.
 Future work needs to be carried out on PUMA using a new construct to confirm
whether it has any significant role in apoptosis induced by Dex and MEK
inhibitors in ALL cells.
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Discussion

Glucocorticoids have been used in chemotherapy for leukemia, lymphoma, and
myeloma for decades. Although they are effective in the initial stages, resistance often
emerges, and the molecular mechanisms of sensitivity/resistance to this agent are still not
fully understood. We and others have demonstrated that BIM, a BH3-only pro-apoptotic
BCL-2 family, is transcriptionally induced by Dex treatment in various cell types and
plays a critical role in Dex-induced cell death. The activity of BIM is regulated not only
by transcription, but also by post-translational mechanisms.

Among these, ERK-

mediated phosphorylation, ubiquitylation, and subsequent protein degradation has been
demonstrated in a variety of cells and MEK inhibitors abrogate such regulation.12,

14-16

Thus, we hypothesized combined treatment with Dex and MEK inhibitors might act
synergistically in their cell killing activity. We demonstrate here that Dex interacts in a
highly synergistic manner with a clinically relevant MEK inhibitor (i.e. PD184352) to
induce apoptosis in CCRF-CEM T-ALL cells.
The observation that the inhibition of cell death correlated well with the reduction
of BIM expression by shRNA in clone 2 and clone 15 (Fig. 9a and 9b) strongly suggests
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that BIM is a central regulator in this regimen at least in CCRF-CEM T-ALL cells.
Recent results involving epithelial breast cancer cells suggest that BAD phosphorylation
status represents the primary integrator of cell death following interruption of the AKT
and ERK pathways. However, down-regulation of BAD with shRNA, in marked contrast
to BIM, failed to protect CEM cells from Dex/PD184352-mediated lethality (Figure 10 a,
10b), suggesting that BAD is not a critical molecule in lethality in this setting.
Differences between current and previous reports may therefore reflect cell type-specific
roles of BAD in integrating death signals following concomitant interruption of the
MEK/ERK and AKT pathways.
PUMA seems to be dispensable for normal development and health, as pumadeficient mice are born with normal appearance and body weight, and they also exhibit
normal cellularity and composition of hemopoietic organs. It has been shown that the
level of puma mRNA increases in primary murine thymocytes exposed to Dex and nonmalignant thymocytes from PUMA-deficient mice are resistant to Dex-induced
apoptosis.34 However, the expression of PUMA in CEM cells were not changed by Dextreatment in CEM cells (Fig. 7), and it has been recently reported that puma mRNA is not
regulated in Dex-treated ALL patients.

Thus, the human puma gene is not a

transcriptional target of the GR, and if Puma contributes to GC-induced apoptosis in
human ALL, it does so in a transcription-independent manner. Hence, PUMA might play
a minor role in the apoptosis induced by co-treatment with Dex and MEK inhibitors.
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It is widely recognized that the RAS/RAF/MEK/ERK signaling pathway mediates
survival signaling in diverse transformed cell types. The implication of the present
findings is that in ALL cells, phosphorylation/degradation of BIM mediated by ERK may
represent a pro-survival mechanism by which such cells escape the lethal consequences
of GC treatment. A corollary of this hypothesis is that MEK inhibition may potentiate
the lethal effects of Dex and potentially other novel agents by preventing BIM
phosphorylation/degradation.35-41 Thus, BIM phosphorylation/expression status may
represent a determinant of the activity of such strategies. If validated, this concept could
have implications for the development of novel anti-leukemia regimens involving the
combined

administration

of

clinically

relevant

agents

targeting

at

the

RAS/RAF/MEK/ERK pathway (e.g. MEK inhibitors, farnesyltransferase inhibitors,
HMG CoA-reductase inhibitors) and GC. A recent study has demonstrated that the
receptor tyrosine kinase inhibitor, SU11657 (potentially inactivating the RAS pathway)
interacts synergistically with Dex to modulate signaling through BIM and to induce
apoptosis in a highly GC-resistant ALL xenograft model.42 BIM also plays an important
role in cell death induced by other chemotherapeutic drugs such as STI571 (imatinib
mesylate)43-45 and histone deacetylase inhibitors (HDACI).46,47 In these cases, BIM is
transcriptionally induced through FOXO and E2F, respectively. If our hypothesis that
combination of BIM up-regulation and stabilization synergistically promotes cell death is
validated, it will be interesting to test whether combinations of STI571 or HDACI with
MEK inhibitors interacts synergistically in ALL cells. In fact, it has been shown that this
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is the case in BCR/ABL+ leukemia cells and other adherent malignant cells.48,49 To date,
several pharmacological MEK inhibitors including PD184352 (or CI-1040), PD0325901,
and AZD6244 (ARRY142886) have been developed clinically.28-30 Results of early
clinical trials indicate that it is feasible to achieve the desired pharmacodynamic effect
(e.g. ERK inactivation) at well-tolerated doses of MEK inhibitors. Collectively, our
findings could have implications for understanding the mechanisms underlying
synergistic interactions between MEK inhibitors and other targeted agents in ALL and
potentially other hematologic malignancies.
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